|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2021 L Street NW, Suite 900 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 59171-12
|
||||||||
|
6. House ID# 352060000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Suzanne M. Leous |
Date | 1/19/2018 2:21:57 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2018 Funding for the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Agency for Healthcare Research and Quality (AHRQ), Health Resources and Services Administration (HRSA)
Public Health Program Funding
Federal Research Funding
Further Continuing Appropriations Act, 2018 (H.J.Res.123) (Continuing Resolution through December 22, 2017)
Further Continuing Appropriations Act, 2018 (H.R. 1370) (Continuing Resolution through January 19, 2018)
Further Additional Supplemental Appropriations for Disaster Relief Requirements, 2017 (H.R. 4667)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
Suzanne |
Leous |
MPA |
|
|
LaTasha |
Lee |
PhD |
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Sickle Cell Disease/Trait Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410)
H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness
Hematology/Oncology Treatment Issues
General Hematology Public Health and Research Issues
Clinical Trials Regulations
Regulation of Laboratory Developed Tests
Cancer "Moonshot" Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Suzanne |
Leous |
MPA |
|
|
Stephanie |
Kaplan |
|
|
|
LaTasha |
Lee |
PhD |
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Protect Access to Cellular Transplant (PACT) Act (H.R. 4215)
Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (P.L. 114-10)
Implementation of Patient Protection and Affordable Care Act (P.L. 111-148)
Repeal of Patient Protection and Affordable Care Act (P.L. 111-148)
American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628)
Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform
Bipartisan Health Care Stabilization Act (proposed by Senators Alexander and Murray)
CMS National Coverage Determination
Medicaid Coverage for Sickle Cell Disease
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
LaTasha |
Lee |
PhD |
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410)
H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness
S.Res. 27, Designating September 2017 as "Sickle Cell Disease Awareness Month"
Cancer Drug Parity Act (H.R. 1409)
Patients Access to Treatment Act (H.R. 2999)
Implementation of Patient Protection and Affordable Care Act (P.L. 111-148)
Repeal of Patient Protection and Affordable Care Act (P.L. 111-148)
American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628)
Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform
Bipartisan Health Care Stabilization Act (proposed by Senators Alexander and Murray)
Hematology and Oncology Drug Research and Approval Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144)
Clinical Trials Regulations and Coverage
Issues Impacting Coverage for Hematologic Diseases and Conditions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
LaTasha |
Lee |
PhD |
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Tax Cuts and Jobs Act (H.R. 1)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Leslie |
Brady |
MPH |
|
|
Tracy |
Roades |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |